ACE-083

DRUG4 trials

Sponsors

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Conditions

Charcot-Marie-Tooth DiseaseFacioscapulohumeral Muscular DystrophyMusculoskeletal Diseases

Phase 1

Phase 1 Study of ACE-083 in Healthy Subjects

CompletedNCT02257489

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAMusculoskeletal Diseases

Start: 2014-09-30End: 2016-04-30Updated: 2022-09-23

Phase 2

Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)

TerminatedNCT02927080

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAFacioscapulohumeral Muscular Dystrophy

Start: 2016-11-30End: 2019-10-09Updated: 2022-09-26

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

TerminatedNCT03124459

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USACharcot-Marie-Tooth Disease

Start: 2017-07-31End: 2020-03-11Updated: 2022-09-26

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

TerminatedNCT03943290

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USACharcot-Marie-Tooth Disease, Facioscapulohumeral Muscular Dystrophy

Start: 2019-05-10End: 2020-03-11Updated: 2022-09-26

Related Papers

Population <scp>PK</scp> and <scp>PD</scp> Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy

Clinical Pharmacology & Therapeutics2022-09-157 citations

Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease.

2022-06-0616 citations

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.

2019-09-1038 citations